中国造埃博拉药物挽救生命却卷入专利纠纷_时事

中国造埃博拉药物挽救生命却卷入专利纠纷

Then China jumped in. The scarcity of ZMapp was “a spark, like lightning to me, said BoyanZhang, chief scientific officer at Beijing Mabworks. Supported by Chinese government grants,the company had developed mammalian cells capable of quickly producing antibodies targetedagainst cancer and viral diseases in humans, and its leaders decided to use the same processto develop an Ebola remedy.

中国因此投入生产。天广实的首席科学顾问张博彦表示，ZMapp的稀缺“让我灵光乍现。在中国政府的支持下，这家公司先前研发出一种哺乳类细胞，可以快速制造对抗癌症与病毒性疾患的抗体。公司高层决定利用同一方法开发埃博拉的疗法。

China, highly attuned to infectious diseases since the outbreak of severe acute respiratorysyndrome in 2003, had many citizens working in West Africa. “The entire country wasmobilized, Mifang Liang of the Chinese Center for Disease Control and Prevention said at theChina-U.S. Relations Conference in Houston last month.

经历2003年严重急性呼吸综合症爆发后对传染病有深刻了解的中国，有许多国民在西非工作。“整个国家都动员起来，中国疾病预防控制中心研究员梁米芳上个月在休斯顿的中美关系研讨会(China-U.S. RelationsConference)上表示。

The Chinese government issued a directive last summer that helped inspire the production notonly of MIL77 but also of an Ebola vaccine, which is currently in human safety studies; rapidEbola diagnostic tests; and copies of antiviral drugs made by companies in other countries. Dr.Zijian Feng, deputy general director of the China C.D.C., said involvement in emergencypublic health assistance served to “elevate our presence in the international stage and alsoelevate our capabilities.